Cancer Biomarkers Market with Foreknown 11.9% CAGR in 2019-2026

admin | December 12, 2019 | 0 | Pharma

Spread the love

The global cancer biomarkers market is expected to grow at a CAGR of around 11.9% from 2019 to 2026 and reach the market value of around US$ 29.8 Bn by 2026.

Free Download Sample Report Pages for Better understanding@ https://www.acumenresearchandconsulting.com/request-sample/1607

North America dominated the cancer biomarkers market in 2018 due to high ongoing research in the development of cancer biomarkers, mergers & collaborations for the development and commercialization of products, favorable reimbursement for cancer diagnosis & treatment, and awareness about companion diagnostics and personalized medicines. For instance, in January 2017, Gene News launched a blood-based biomarker test, Breast Sentry, for risk assessment of breast cancer in the U.S. Asia Pacific is anticipated to observe the fastest growth during the forecasts period in the market. This can be attributed to increasing investment by market players in this region due to the availability of large targeted patient population, supportive government regulations in many countries, and increasing disposable income. According to the recent cancer data published by the World Health Organization (WHO) in 2018, about half of new cases and more than half of cancer deaths in 2018 are estimated to occur in Asia as the region has about 60% of the global population.

Based on type, the cancer biomarkers market has been segmented into protein biomarker, genetic biomarker, and others. Other segment includes viral, cell, and carbohydrate biomarkers. Protein biomarkers accounted for the largest segment in the market in 2018 due to its ability for early diagnosis and the presence of several commercial biomarkers.

View Detail Information with Complete TOC@ https://www.acumenresearchandconsulting.com/cancer-biomarkers-market

On the basis of technology used for profiling, the market has been categorized into omics technology, immunoassay, imaging technologies, and cytogenetic testing. The omics technology segment accounted for the largest share of the market in 2018. This can be attributed to a revolution in the omics technologies since the last decade responsible for the increase in the applications of biomarkers.

Based on the application, the prognostics segment held the maximum share of the market in 2018 and is expected to maintain its dominance during the forecast period. However, the diagnosis segment is anticipated to witness the fastest growth in coming years.

Based on the cancer type, breast cancer accounted for the largest share of the market due to more awareness about screening, availability of commercialized products, and high sensitivity of markers to detect breast cancer. Lung cancer, colorectal cancer, prostate cancer, leukemia, thyroid gland cancer, kidney cancer, and bladder cancer are some of the other cancers where biomarkers are used for various applications.

The cancer biomarkers market dominated by Abbott Laboratories, Agilent Technologies, Becton Dickinson and Company, Hologic, Illumina, Merck & Co., Qiagen N.V., Roche Diagnostics, and Thermo Fisher Scientific. Growing need of cancer biomarkers for the detection and monitoring of cancer is the major reason to invest in the market. Research and development activities, commercialization of sensitive products, and collaborations for the development & commercialization have been the most adopted strategies by industry players to enhance their share in the market.

Related Reports

  • Viral Vector & Plasmid DNA Manufacturing Market – The global market size is estimated to grow at CAGR above 21.4 % over the forecast time frame 2019-2026 and reach the market value around USD 1.8 billion by 2026.
  • Cancer Diagnostics Market – The global market size is expected to worth around USD 250.3 billion by 2026. The market is predictable to showcase a CAGR of 7.2% during the forthcoming years 2019 to 2026.
  • Biomarkers Market Size, Share, Forecast Research Report 2024

Some of the key observations regarding cancer biomarkers industry include:

  • In May 2019, QIAGEN launched the first FDA approved therascreen PIK3CA RGQ PCR Kit, a companion diagnostic to support in detecting breast cancer patients who are eligible for the treatment of PIQRAY, a new therapy by Novartis.
  • In May 2019, Roche launched HER2 biomarker test for gastric and breast cancer in the UK. The human epidermal growth factor receptor -2 is a key biomarker detect in gastric and breast cancers and its identification and inhibition can help in the management of aggressive cancers. The test is already launched in Europe, Asia pacific, Middle, East & Africa, and Latin America.
  • In May 2019, Biotech Support Group (BSG) signed a research collaboration agreement with Leiden University Medical Center (LUMC). Both the organization will work to develop protein biomarkers.
  • In November 2018, Biocartis Group NV entered into an agreement with the AstraZeneca to obtain fast lung cancer molecular diagnostic biomarker results across Europe. The study is expected to initiate at various sites in France, Italy, Belgium, and Germany.
  • In June 2018, MDxHealth signed an agreement with Philips for phosphodiesterase-4D7 (PDE4D7), a prognostic prostate cancer biomarker. The agreement facilitates the launch of MDxHealth’s InformMDx, a test for prostate cancer.
  • In June 2017, Trovagene signed an agreement with AstraZeneca to provide the company’s urine based ctDNA biomarker test to AstraZeneca for use in its study. According to the deal, AstraZeneca will use Trovagene’s Trovera EGFR urine liquid biopsy test and evaluate whether urine and blood combination testing are as effective as tissue testing in identifying EGFR T790M mutation status.

Request for Customization@ https://www.acumenresearchandconsulting.com/request-customization/1607

The report is readily available and can be dispatched immediately after payment confirmation.

Buy this premium research report@ https://www.acumenresearchandconsulting.com/buy-now/0/1607

If you would like to place an order or have any questions, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157 OR +1 408 900 9135

For Latest Update Follow Us:

https://twitter.com/AcumenRC

https://www.facebook.com/acumenresearchandconsulting

https://www.linkedin.com/company/acumen-research-and-consulting/

Tags:

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *

Acumen Research and Consulting

  • Esoteric Testing Market Will Touch US$ 40 Bn in 2026

    The worldwide Esoteric Testing Market is set to surpass US$ 40 billion by the year end of 2026 and growing at a CAGR of 10 % from 2019-2026. Several players, including Laboratory Corporation of America, BioMONTR and American Esoteric Laboratories (AEL), OPKO Health, Nordic Laboratories, Miraca Holdings, ACM, Fulgent Genetics, Genomic health, Invitae, Mayo Medical … Continue reading "Esoteric Testing Market Will Touch US$ 40 Bn in 2026"

  • End-of-Line Packaging Market Hit $6.4 Bn in 2026

    The worldwide End-of-Line Packaging Market is set to surpass US$ 6.4 billion by the year end of 2026 and growing at a CAGR of 4 % from 2019-2026. Several players, including Combi Packaging Systems LLC, DS Smith plc, Bosch Packaging Technology Krones AG, Mach Inc., Optima Packaging Group GmbH, Gebo Cermex, IMA S.p.A., Festo Corporation, … Continue reading "End-of-Line Packaging Market Hit $6.4 Bn in 2026"

  • Global Craniomaxillofacial (CMF) Devices Market Worth $3.5 Bn by 2026

    The worldwide Craniomaxillofacial (CMF) Devices Market is set to surpass US$ 3.5 billion by the year end of 2026 and growing at a CAGR of 5.7 % from 2019-2026. Several players, including DePuy Synthes (J&J), Medtronic, Stryker and Zimmer-Biomet, companies, research institutes, contract manufacturing organizations, and non-profit organizations, are playing a critical role in the … Continue reading "Global Craniomaxillofacial (CMF) Devices Market Worth $3.5 Bn by 2026"

  • Real-time PCR (qPCR) and Digital PCR (dPCR) Industry Reach US$ 4.2 billion by 2026

    According to Acumen Research and Consulting, the global Real-time PCR (qPCR) & Digital PCR (dPCR) market is expected to grow at noteworthy CAGR around 8.1 % throughout the forecast period and reach around US$ 4.2 billion by 2026. The report analyzes and forecasts the Real-time PCR (qPCR) and Digital PCR (dPCR) market at global and regional … Continue reading "Real-time PCR (qPCR) and Digital PCR (dPCR) Industry Reach US$ 4.2 billion by 2026"

  • Sports Medicine Industry Reach US$ 13 billion by 2026

    The global sports medicine market value is expected to reach around US$ 13 billion by 2026 and growing at a CAGR of 7% throughout the forecast period 2019-2026. The report analyzes and forecasts the Sports Medicine market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) … Continue reading "Sports Medicine Industry Reach US$ 13 billion by 2026"

  • Meningococcal Vaccines Industry Value is Estimated to Hit USD 9.37 billion by 2026

    The global meningococcal vaccines market value is estimated to hit USD 9.37 billion by 2026 and expected to grow at a CAGR of 12.3% over period 2019 to 2026. The report analyzes and forecasts the Meningococcal Vaccines market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ … Continue reading "Meningococcal Vaccines Industry Value is Estimated to Hit USD 9.37 billion by 2026"

  • Transcatheter Heart Valve Replacement Systems Industry Reach US$ 11 billion by 2019-2026

    According to Acumen Research and Consulting, the global transcatheter heart valve replacement market size is expected to reach around US$ 11 billion by 2026 with 12.9 % of CAGR throughout the forecast period 2019-2026. The report analyzes and forecasts the Transcatheter Heart Valve Replacement Systems market at global and regional levels. The market has been forecast … Continue reading "Transcatheter Heart Valve Replacement Systems Industry Reach US$ 11 billion by 2019-2026"

  • Coronary Stents Industry Size is Expected US$ 16.88 billion by 2025

    The global coronary stents market size is expected to worth around US$ 16.88 billion by 2025, and market is registering growth at 7% from 2018 to 2025. The report analyzes and forecasts the Coronary Stents market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from … Continue reading "Coronary Stents Industry Size is Expected US$ 16.88 billion by 2025"

  • Biosensors Industry Reach around US$ 32 billion by 2019-2026

    According to Acumen Research and Consulting, the global biosensors market is expected to grow at noteworthy CAGR around 7.8 % throughout the forecast period and reach around US$ 32 billion by 2026. The report analyzes and forecasts the Biosensors market at global and regional levels. The market has been forecast based on volume (Tons) and value … Continue reading "Biosensors Industry Reach around US$ 32 billion by 2019-2026"

  • Real-time PCR (qPCR) and Digital PCR (dPCR) Industry Reach US$ 4.2 billion by 2026

    According to Acumen Research and Consulting, the global Real-time PCR (qPCR) & Digital PCR (dPCR) market is expected to grow at noteworthy CAGR around 8.1 % throughout the forecast period and reach around US$ 4.2 billion by 2026. The report analyzes and forecasts the Real-time PCR (qPCR) and Digital PCR (dPCR) market at global and regional … Continue reading "Real-time PCR (qPCR) and Digital PCR (dPCR) Industry Reach US$ 4.2 billion by 2026"

Recent Posts